(Q37015628)

English

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials

scientific article published on January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

0 references

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials (English)

1 reference

Europe PubMed Central

17 August 2017

0 references

circulatory system

1 reference

based on heuristic

inferred from title

Kathleen I. Pritchard

object named as

Kathleen I Pritchard

4

0 references

object named as

Emilio Bria

2

0 references

Diana Giannarelli

object named as

Diana Giannarelli

11

0 references

author name string

Federica Cuppone

1

1 reference

Europe PubMed Central

17 August 2017

Sunil Verma

3

1 reference

Europe PubMed Central

17 August 2017

Sonal Gandhi

5

1 reference

Europe PubMed Central

17 August 2017

Paolo Carlini

6

1 reference

Europe PubMed Central

17 August 2017

Michele Milella

7

1 reference

Europe PubMed Central

17 August 2017

Cecilia Nisticò

8

1 reference

Europe PubMed Central

17 August 2017

Edmondo Terzoli

9

1 reference

Europe PubMed Central

17 August 2017

Francesco Cognetti

10

1 reference

Europe PubMed Central

17 August 2017

language of work or name

0 references

publication date

1 January 2008

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

112

1 reference

Europe PubMed Central

17 August 2017

260-267

1 reference

Europe PubMed Central

17 August 2017

2

1 reference

Europe PubMed Central

17 August 2017

Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

21 January 2018

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

21 January 2018

Systematic Reviews in Health Care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular safety profiles of aromatase inhibitors : a comparative review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular health and aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

ATAC trial update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trials stopped early for benefit: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of vascular and neoplastic events associated with tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analyses based on abstracted data: a step in the right direction, but only a first step.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant Chemotherapy for Bladder Cancer: The Chance for Meta-analyses Comparison

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23171

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23171

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37015628&oldid=2140509847"